Novartis bets on experimental cancer treatment from US firm
Keystone / Georgios Kefalas
The Swiss pharma giant has made an offer to buy the rights to a tumor inhibiting treatment from Clovis Oncology in Colorado, which has filed for bankruptcy protection.
This content was published on
1 minute
Keystone-SDA/ac
Português
pt
Novartis aposta em tratamento experimental do câncer de empresa americana
Novartis has committed to pay $50 million (just under CHF47 million) upfront for all rights to the experimental cancer treatment. In addition, the Basel-based company has agreed to pay out up to an additional $333.75 million upon the successful reaching of development and regulatory milestones and $297 million in later sales milestones.
The experimental treatment and imaging agent known as FAP-2286 is in a phase I/II study, called Lumière, for its ability to bind to a fibroblast activating protein (FAP), Clovis said in a statement on Monday. It is the first peptide-targeted radionuclide therapy (PTRT) and imaging agent targeting FAP to enter clinical development.
The acquisition by Novartis is what is known as a “stalking horse purchase”. Clovis intends to submit the Novartis offer to other potential buyers in the hope of attracting competing proposals. These will be reviewed with advisers in a proceeding supervised by the U.S. Bankruptcy Court for the District of Delaware.
Popular Stories
More
Life & Aging
Zurich: how the world capital of housing shortages is tackling the problem
Is your place of origin, your Heimatort, important to you?
Every Swiss citizen has a Heimatort, a place of origin, but many have never visited theirs. What’s your relationship with your Heimatort? What does it mean to you?
What factors should be taken into account when inheriting Swiss citizenship abroad?
Should there be a limit to the passing on of Swiss citizenship? Or is the current practice too strict and it should still be possible to register after the age of 25?
Men in Switzerland under pressure to uphold social standing
This content was published on
A study from the University of Bern reveals that men in relatively gender-equal countries face significant pressure to maintain their high social status.
Ivory Coast court bars former Credit Suisse CEO from presidential race
This content was published on
The court removed opposition politician and former CEO of Credit Suisse Tidjane Thiam from the electoral roll, citing the loss of his Ivorian nationality.
Novartis and Sanofi call for higher drug prices in Europe
This content was published on
Swiss and French pharmaceutical companies Novartis and Sanofi argue that the EU should adjust its drug prices to better align with those in the US.
WHO braces for staff cuts in Geneva amid US funding withdrawal
This content was published on
WHO’s Director-General warned US budget cuts are putting the agency in financial trouble, leading to management cuts in Geneva.
Parmelin meets Swiss businesses in US as IMF predicts 0.9% growth for Switzerland
This content was published on
Economics Minister Guy Parmelin met Swiss businesses in the US during IMF and World Bank meetings. The IMF now forecasts 0.9% GDP growth for Switzerland.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.